{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:59:19Z","timestamp":1794488359533,"version":"4.9.1"},"reference-count":76,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Macrocycles are emerging as a prominent modality in drug discovery, including for conventionally druggable targets for which simpler, acyclic ligands are readily discoverable. Given the additional synthetic challenges associated with macrocyclic chemotypes, we address what benefits macrocycles provided for these highly druggable targets. To do this, we examine the effects of macrocyclization on inhibitors of highly druggable kinase targets. For each example, we isolate closely matched acyclic\/macrocyclic compound pairs, allowing us to pinpoint the effects of macrocyclization on binding affinity, selectivity, and ADME properties absent confounding factors. Our findings show that while the impact of macrocyclization on potency is variable, a profound effect on selectivity is common. Macrocyclization can also bring benefits for membrane permeability, efflux ratio, blood-brain barrier penetrance, and metabolic stability. These findings lead us to propose specific circumstances in which a drug discoverer targeting kinases or other conventionally druggable target classes should consider a macrocycle approach.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.4c02886","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T13:53:17Z","timestamp":1753969997000},"page":"15260-15284","source":"Crossref","is-referenced-by-count":12,"title":["Macrocycles\nfor Conventionally Druggable Targets:\nLessons from Macrocyclic Kinase Inhibitors"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-7940","authenticated-orcid":true,"given":"Lauren A.","family":"Viarengo-Baker","sequence":"first","affiliation":[{"name":"Boston University , , 590 Commonwealth Avenue , , ,","place":["Boston, Massachusetts, United States, 02215"]},{"name":"Relay Therapeutics , 399 Binney Street , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-4369","authenticated-orcid":true,"given":"Adrian","family":"Whitty","sequence":"additional","affiliation":[{"name":"Boston University , , 590 Commonwealth Avenue , , ,","place":["Boston, Massachusetts, United States, 02215"]},{"name":"Boston University , , 590 Commonwealth Avenue , , ,","place":["Boston, Massachusetts, United States, 02215"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"7","key":"2026073103040202400_cit1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrd2590","article-title":"The Exploration\nof Macrocycles for Drug Discovery - An Underexploited Structural Class","volume":"7","author":"Driggers","year":"2008","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"1\u20133","key":"2026073103040202400_cit2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11030-005-1314-x","article-title":"What Can a Chemist\nLearn from Nature\u2019s Macrocycles?--A Brief","volume":"9","author":"Wessjohann","year":"2005","journal-title":"Conceptual View. Mol. Divers"},{"issue":"7","key":"2026073103040202400_cit3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/jm1012374","article-title":"Macrocycles Are\nGreat Cycles: Applications, Opportunities,\nand Challenges of Synthetic Macrocycles in Drug Discovery","volume":"54","author":"Marsault","year":"2011","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026073103040202400_cit4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/jm400887j","article-title":"Macrocyclic Drugs and\nClinical Candidates: What Can\nMedicinal Chemists Learn from Their Properties?","volume":"57","author":"Giordanetto","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026073103040202400_cit5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nchembio.1584","article-title":"How Proteins Bind Macrocycles","volume":"10","author":"Villar","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"2026073103040202400_cit6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cbpa.2008.03.016","article-title":"The Impact\nof Natural Products upon Modern Drug Discovery","volume":"12","author":"Ganesan","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"8","key":"2026073103040202400_cit7","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1021\/acs.jmedchem.3c00134","article-title":"Macrocycles in Drug\nDiscovery\u2500Learning from the Past for the Future","volume":"66","author":"Garcia Jimenez","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026073103040202400_cit8","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1039\/D0SC05788F","article-title":"Defining and Navigating\nMacrocycle Chemical Space","volume":"12","author":"Viarengo-Baker","year":"2021","journal-title":"Chem. Sci."},{"issue":"Suppl","key":"2026073103040202400_cit9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and\nComputational Approaches to Estimate Solubility and Permeability in\nDrug Discovery and Development Settings","volume":"64","author":"Lipinski","year":"1997","journal-title":"Adv.\nDrug Delivery Rev."},{"issue":"12","key":"2026073103040202400_cit10","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence\nthe Oral Bioavailability\nof Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026073103040202400_cit11","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic Peptides as Drug Candidates: Recent Progress\nand Remaining Challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"2026073103040202400_cit12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tips.2021.11.008","article-title":"Targeting Intracellular Protein-Protein Interactions with Macrocyclic\nPeptides","volume":"43","author":"Buyanova","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"17","key":"2026073103040202400_cit13","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1021\/acs.jmedchem.4c01163","article-title":"The Missing\nLink(Er): A Roadmap to Macrocyclization in Drug Discovery","volume":"67","author":"Brudy","year":"2024","journal-title":"J. Med. Chem."},{"issue":"37","key":"2026073103040202400_cit14","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1039\/C7OB00056A","article-title":"Progress towards\nthe Broad Use of\nNon-Peptide Synthetic Macrocycles in Drug Discovery","volume":"15","author":"Whitty","year":"2017","journal-title":"Org. Biomol. Chem."},{"issue":"23","key":"2026073103040202400_cit15","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1021\/acs.jmedchem.5b00586","article-title":"New Frontiers in Druggability","volume":"58","author":"Kozakov","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.addr.2016.03.013","article-title":"Cell Permeability beyond\nthe Rule of 5","volume":"101","author":"Matsson","year":"2016","journal-title":"Adv. Drug Delivery Rev."},{"issue":"11","key":"2026073103040202400_cit17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4155\/fmc.12.93","article-title":"Macrocycles in New\nDrug Discovery","volume":"4","author":"Mallinson","year":"2012","journal-title":"Future Med. Chem."},{"issue":"15","key":"2026073103040202400_cit18","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1021\/jm300655h","article-title":"Critical Effect\nof Peptide Cyclization on the Potency\nof Peptide Inhibitors against Dengue Virus NS2B-NS3 Protease","volume":"55","author":"Xu","year":"2012","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026073103040202400_cit19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.chembiol.2016.07.017","article-title":"Structural and Biochemical\nBasis for Intracellular Kinase Inhibition by Src-Specific Peptidic\nMacrocycles","volume":"23","author":"Aleem","year":"2016","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"2026073103040202400_cit20","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1021\/acs.jmedchem.4c01822","article-title":"Macrocyclization as a Strategy for Kinetic Solubility\nImprovement: A Comparative Analysis of Matched Molecular Pairs","volume":"68","author":"Walz","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit21","doi-asserted-by":"publisher","DOI":"10.1039\/9781782623113","volume-title":"Macrocycles in Drug Discovery","author":"Levin","year":"2015"},{"issue":"29","key":"2026073103040202400_cit22","doi-asserted-by":"publisher","first-page":"12125","DOI":"10.1021\/ja303200d","article-title":"Intestinal Permeability\nof Cyclic Peptides: Common Key Backbone Motifs Identified","volume":"134","author":"Beck","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"22","key":"2026073103040202400_cit23","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.1021\/acs.jmedchem.8b01732","article-title":"Why Some Targets Benefit\nfrom beyond Rule of Five Drugs","volume":"62","author":"Egbert","year":"2019","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026073103040202400_cit24","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1021\/acs.jmedchem.1c00217","article-title":"Synthetic\nOpportunities and Challenges\nfor Macrocyclic Kinase Inhibitors","volume":"64","author":"Amrhein","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit25","first-page":"141","article-title":"Designed Macrocyclic\nKinase Inhibitors","volume-title":"Macrocycles in Drug\nDiscovery","author":"Poulsen","year":"2015"},{"key":"2026073103040202400_cit26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties\nof FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2023 Update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"2026073103040202400_cit27","unstructured":"https:\/\/www.ppu.mrc.ac.uk\/list-clinically-approved-kinase-inhibitors."},{"key":"2026073103040202400_cit28","unstructured":"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products."},{"key":"2026073103040202400_cit29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification\nof Small Molecule Protein Kinase Inhibitors Based upon the Structures\nof Their Drug-Enzyme Complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"2026073103040202400_cit30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1039\/d3md00457k","article-title":"Kinase Inhibitor Macrocycles:\nA Perspective on Limiting Conformational Flexibility When Targeting\nthe Kinome with Small Molecules","volume":"15","author":"Acharya","year":"2023","journal-title":"RSC Med. Chem."},{"key":"2026073103040202400_cit31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/ph16071009","article-title":"An Intriguing Purview on the Design of Macrocyclic\nInhibitors for Unexplored Protein Kinases through Their Binding Site\nComparison","volume":"16","author":"Bhujbal","year":"2023","journal-title":"Pharmaceuticals."},{"key":"2026073103040202400_cit32","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3390\/molecules27092837","article-title":"An Insight into the Medicinal Chemistry\nPerspective of Macrocyclic Derivatives with Antitumor Activity: A\nSystematic Review","volume":"27","author":"Liang","year":"2022","journal-title":"Molecules."},{"issue":"8","key":"2026073103040202400_cit33","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1021\/acsptsci.3c00078","article-title":"Rigid Scaffolds\nAre Promising for Designing Macrocyclic\nKinase Inhibitors","volume":"6","author":"Zhao","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"15","key":"2026073103040202400_cit34","doi-asserted-by":"publisher","first-page":"12534","DOI":"10.1021\/acs.jmedchem.4c00411","article-title":"Back-Pocket\nOptimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent\nEPHA2\/GAK Kinase Inhibitors","volume":"67","author":"Gerninghaus","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit35","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.csbj.2023.11.028","article-title":"Structural\nInsight into the Macrocyclic Inhibitor TPX-0022\nof c-Met and c-Src","volume":"21","author":"Qu","year":"2023","journal-title":"Comput. Struct. Biotechnol.\nJ."},{"issue":"12","key":"2026073103040202400_cit36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/cmdc.202300343","article-title":"Structural\nAnalysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase","volume":"19","author":"Beyett","year":"2024","journal-title":"ChemMedChem."},{"issue":"11","key":"2026073103040202400_cit37","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H\u20138,4-(Metheno)Pyrazolo[4,3-h][2,5,11]-Benzoxadiazacyclotetradecine-3-Carbonitrile\n(PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase\n(ALK) and c-Ros Oncogene 1 (ROS1) with Preclinical Brain Exposure\nand Broad-Spectrum Potency against ALK-Resistant Mutations","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026073103040202400_cit38","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1021\/jm200326p","article-title":"Discovery\nof the Macrocycle 11-(2-Pyrrolidin-1-Yl-Ethoxy)-14,19-Dioxa-5,7,26-Triaza-Tetracyclo[19.3.1.1(2,6).1(8,12)]Heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-Decaene\n(SB1518), a Potent Janus Kinase 2\/Fms-like Tyrosine Kinase-3 (JAK2\/FLT3)\nInhibitor for the Treatment of Myelofibrosis and Lymphoma","volume":"54","author":"William","year":"2011","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026073103040202400_cit39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/sj.bjc.6605867","article-title":"Phase i and Pharmacological Study of the Broad-Spectrum\nTyrosine Kinase Inhibitor JNJ-26483327 in Patients with Advanced Solid\nTumours","volume":"103","author":"Konings","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"1","key":"2026073103040202400_cit40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1021\/jm201112g","article-title":"Discovery of Kinase Spectrum Selective\nMacrocycle (16E)-14-Methyl-20-Oxa-5, 7,14,26-Tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]Heptacosa-1(25),2(26),3,5,8(27),\n9,11,16,21,23-Decaene (SB1317\/TG02), a Potent Inhibitor of Cyclin\nDependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine\nKinase-3 (FLT3) for the Treatment of Cancer","volume":"55","author":"William","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026073103040202400_cit41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00894-012-1528-7","article-title":"Structure-Based Design of Nitrogen-Linked\nMacrocyclic Kinase Inhibitors Leading to the Clinical Candidate SB1317\/TG02,\na Potent Inhibitor of Cyclin Dependant Kinases (CDKs), Janus Kinase\n2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3)","volume":"19","author":"Poulsen","year":"2013","journal-title":"J. Mol. Model."},{"issue":"10","key":"2026073103040202400_cit42","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (Tpx-0005) Is a next-Generation Ros1\/Trk\/Alk\nInhibitor That Potently Inhibits Ros1\/Trk\/Alk Solvent-Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discovery"},{"key":"2026073103040202400_cit43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/9780470122884.ch4","article-title":"Binding\nEnergy, Specificity, and Enzymic Catalysis: The Circe Effect","volume":"43","author":"Jencks","year":"1975","journal-title":"Adv. Enzymol. Relat. Areas Mol. Biol."},{"issue":"2","key":"2026073103040202400_cit44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/prot.10086","article-title":"Contributions\nto the Binding Free\nEnergy of Ligands to Avidin and Streptavidin","volume":"47","author":"Lazaridis","year":"2002","journal-title":"Proteins"},{"issue":"10","key":"2026073103040202400_cit45","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1021\/jacs.0c09799","article-title":"Recapitulating the\nBinding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided\nby NMR, X-Ray Crystallography, and Machine Learning","volume":"143","author":"Ortet","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"2026073103040202400_cit46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1021\/acsmedchemlett.5b00403","article-title":"Discovery and Optimization of Macrocyclic Quinoxaline-Pyrrolo-Dihydropiperidinones\nas Potent Pim-1\/2 Kinase Inhibitors","volume":"7","author":"Cee","year":"2016","journal-title":"ACS Med.\nChem. Lett."},{"issue":"11","key":"2026073103040202400_cit47","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1021\/acsmedchemlett.1c00412","article-title":"Macrocyclization as a Source of Desired Polypharmacology.\nDiscovery of Triple PI3K\/MTOR\/PIM Inhibitors","volume":"12","author":"Marti\u0301nez-Gonza\u0301lez","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"2026073103040202400_cit48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4155\/fmc-2021-0342","article-title":"Development\nof Small Macrocyclic\nKinase Inhibitors","volume":"14","author":"Ma","year":"2022","journal-title":"Future Med. Chem."},{"issue":"12","key":"2026073103040202400_cit49","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1021\/acsmedchemlett.6b00221","article-title":"Design and Synthesis of Novel Macrocyclic Mer Tyrosine\nKinase Inhibitors","volume":"7","author":"Wang","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"2026073103040202400_cit50","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based\nType II TRK Inhibitors That Overcome Clinically Acquired Resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026073103040202400_cit51","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.1021\/acs.jmedchem.1c00434","article-title":"Discovery\nof AZD8154, a Dual PI3K\u03b3\u03b4 Inhibitor for the Treatment\nof Asthma","volume":"64","author":"Perry","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112770","article-title":"Optimization of Pyrazolo[1,5-a]Pyrimidines\nLead to the Identification of a Highly Selective Casein Kinase 2 Inhibitor","volume":"208","author":"Kra\u0308mer","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"2026073103040202400_cit53","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1021\/acsmedchemlett.0c00061","article-title":"Design\nand Development\nof a Macrocyclic Series Targeting Phosphoinositide 3-Kinase \u03b4","volume":"11","author":"Spencer","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"2026073103040202400_cit54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1021\/jm201333e","article-title":"Design, Synthesis, and Anaplastic\nLymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.1\n3,7.1 9,13]Docosa-1(20),3(22),4,6,9(21),10,12,16,18-Nonaene Macrocycles","volume":"55","author":"Breslin","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113109","article-title":"Omipalisib Inspired Macrocycles as\nDual PI3K\/MTOR Inhibitors","volume":"211","author":"A\u0301lvarez","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"2026073103040202400_cit56","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1002\/anie.201200110","article-title":"Structure-Based\nMacrocyclization Yields Hepatitis C Virus NS5B Inhibitors with Improved\nBinding Affinities and Pharmacokinetic Properties","volume":"51","author":"Cummings","year":"2012","journal-title":"Angew. Chemie - Int. Ed."},{"issue":"4","key":"2026073103040202400_cit57","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1021\/jm701093y","article-title":"Backbone Cyclic\nPeptidomimetic Melanocortin-4 Receptor Agonist as a Novel Orally Administrated\nDrug Lead for Treating Obesity","volume":"51","author":"Hess","year":"2008","journal-title":"J. Med. Chem."},{"issue":"39","key":"2026073103040202400_cit58","doi-asserted-by":"publisher","first-page":"13767","DOI":"10.1073\/pnas.0504613102","article-title":"Engineering\nStable Peptide Toxins by Means of Backbone Cyclization: Stabilization\nof the \u03b1-Conotoxin MII","volume":"102","author":"Clark","year":"2005","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."},{"issue":"16","key":"2026073103040202400_cit59","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.4155\/fmc.15.78","article-title":"Beyond\nCyclosporine A: Conformation-Dependent\nPassive Membrane Permeabilities of Cyclic Peptide Natural Products","volume":"7","author":"Ahlbach","year":"2015","journal-title":"Future Med. Chem."},{"issue":"24","key":"2026073103040202400_cit60","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1021\/jm00076a002","article-title":"Solvent-Dependent Conformation and\nHydrogen-Bonding Capacity of Cyclosporin A: Evidence from Partition\nCoefficients and Molecular Dynamics Simulations","volume":"36","author":"El Tayar","year":"1993","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026073103040202400_cit61","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/cphc.201700995","article-title":"Interconversion Rates between Conformational\nStates as Rationale for the Membrane Permeability of Cyclosporines","volume":"18","author":"Witek","year":"2017","journal-title":"ChemPhysChem"},{"issue":"8","key":"2026073103040202400_cit62","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1021\/acs.jpcb.7b12419","article-title":"Conformational\nFlexibility Is a Determinant of Permeability for Cyclosporin","volume":"122","author":"Wang","year":"2018","journal-title":"J. Phys. Chem. B"},{"issue":"18","key":"2026073103040202400_cit63","doi-asserted-by":"publisher","first-page":"13131","DOI":"10.1021\/acs.jmedchem.1c00580","article-title":"Cyclosporin\nStructure and Permeability: From A to Z and Beyond","volume":"64","author":"Corbett","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026073103040202400_cit64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114874","article-title":"Analysis of the Interaction of Cyclosporine\nCongeners with Cell Membrane Models","volume":"218","author":"Nakao","year":"2022","journal-title":"J. Pharm.\nBiomed. Anal."},{"issue":"7","key":"2026073103040202400_cit65","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1039\/c1md00093d","article-title":"Intramolecular\nHydrogen Bonding to Improve Membrane Permeability and Absorption in\nbeyond Rule of Five Chemical Space","volume":"2","author":"Alex","year":"2011","journal-title":"Medchemcomm"},{"key":"2026073103040202400_cit66","doi-asserted-by":"publisher","first-page":"14073","DOI":"10.1021\/ja063076p","article-title":"Conformational Flexibility,\nInternal\nHydrogen Bonding, and Passive Membrane Permeability: Successful in\nSilico Prediction of the Relative Permeabilities of Cyclic Peptides","volume":"128","author":"Rezai","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"2026073103040202400_cit68","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nchembio.2203","article-title":"Structural and Conformational Determinants of Macrocycle\nCell Permeability","volume":"12","author":"Over","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"23","key":"2026073103040202400_cit69","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1002\/chem.201905599","article-title":"Solution Conformations Explain the Chameleonic Behaviour\nof Macrocyclic Drugs","volume":"26","author":"Danelius","year":"2020","journal-title":"Chemistry"},{"issue":"5","key":"2026073103040202400_cit70","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.drudis.2016.02.005","article-title":"Quantifying the Chameleonic Properties of Macrocycles and Other High-Molecular-Weight\nDrugs","volume":"21","author":"Whitty","year":"2016","journal-title":"Drug Discovery Today"},{"issue":"8","key":"2026073103040202400_cit71","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1021\/ja0563455","article-title":"Testing\nthe Conformational Hypothesis of Passive Membrane Permeability Using\nSynthetic Cyclic Peptide Diastereomers","volume":"128","author":"Rezai","year":"2006","journal-title":"J. Am.\nChem. Soc."},{"issue":"1","key":"2026073103040202400_cit72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41570-023-00563-1","article-title":"Molecular Chameleons in Drug Discovery","volume":"8","author":"Poongavanam","year":"2024","journal-title":"Nat. Rev. Chem."},{"issue":"26","key":"2026073103040202400_cit73","doi-asserted-by":"publisher","first-page":"22245","DOI":"10.1021\/acsomega.9b03797","article-title":"Conformation\nof the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments:\nA MD Simulation and NMR Study","volume":"4","author":"Peng","year":"2019","journal-title":"ACS Omega"},{"issue":"15","key":"2026073103040202400_cit74","doi-asserted-by":"publisher","first-page":"10300","DOI":"10.1021\/acs.jmedchem.1c02090","article-title":"Conformational\nEffects on the Passive Membrane Permeability of Synthetic Macrocycles","volume":"65","author":"Rzepiela","year":"2022","journal-title":"J. Med. Chem."},{"issue":"15","key":"2026073103040202400_cit75","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1002\/ange.202012643","article-title":"Connecting\nHydrophobic Surfaces in\nCyclic Peptides Increases Membrane Permeability","volume":"133","author":"Hoang","year":"2021","journal-title":"Angew. Chem."},{"issue":"10","key":"2026073103040202400_cit76","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1039\/D1RA09025A","article-title":"Polar\/Apolar Interfaces Modulate\nthe Conformational Behavior of Cyclic Peptides with Impact on Their\nPassive Membrane Permeability","volume":"12","author":"Linker","year":"2022","journal-title":"RSC Adv."},{"issue":"7","key":"2026073103040202400_cit77","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1021\/acs.jcim.1c00380","article-title":"Large-Scale\nMembrane\nPermeability Prediction of Cyclic Peptides Crossing a Lipid Bilayer\nBased on Enhanced Sampling Molecular Dynamics Simulations","volume":"61","author":"Sugita","year":"2021","journal-title":"J. Chem. Inf. Model."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.4c02886","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/15260\/66298404\/acs.jmedchem.4c02886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/15260\/66298404\/acs.jmedchem.4c02886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:04:10Z","timestamp":1785481450000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/15\/15260\/5234970\/Macrocycles-for-Conventionally-Druggable-Targets"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":76,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,7,31]]},"published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02886","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2025-s26cq","asserted-by":"object"},{"id-type":"doi","id":"10.26434\/chemrxiv-2025-s26cq-v2","asserted-by":"object"}],"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02886.s001","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}